Promising results of ABRAXANE for bladder cancer support efficacy of nab-driven chemo

[News]

Abraxis BioScience, Inc. announced today that findings from a phase 1 randomized trial demonstrated that the nanoparticle albumin bound (nab®) driven chemotherapy, nab-paclitaxel (ABRAXANE® for Injectable Suspension; paclitaxel albumin protein-bound particles for injectable suspension) is well-tolerated and active in the second-line treatment of high-grade, non-muscle-invasive bladder cancer that has been refractory to standard intra-bladder infusion (intravesical) therapy.

More... (http://www.news-medical.net/news/20100604/Promising-results-of-ABRAXANE-for-bladder-cancer-support-efficacy-of-nab-driven-chemotherapy.aspx)